Search bioRxiv⌕ Search

Biology subjects

Akers, W. S.

Publications and source records attributed to Akers, W. S..

4 recordsLinked to original sources

Characterizing the Metabolic Fate and Pharmacokinetics of the RyR2 Inhibitor ent-Verticilide

ent-Verticilide is a synthetic macrocyclic depsipeptide and ryanodine receptor 2 (RyR2) inhibitor with potential therapeutic applications in cardiac arrhythmias. This study characterized its in vitro metabolism and in vivo pharmacokinetics to better understand factors that may influence its disposition. Metabolic stability was evaluated in mouse, rat, dog, and human liver S9 fractions, followed by CYP reaction phenotyping in human liver microsomes and metabolite profiling in human and rat liver S9 fractions. Pharmacokinetics were evaluated in rats following intravenous and oral administration. ent-Verticilide underwent rapid, NADPH-dependent depletion across all species, with in vitro half-lives ranging from 2.1 to 5.3 min. CYP reaction phenotyping indicated that CYP3A was the predominant CYP subfamily involved in its metabolism. Eight putative metabolites were identified in human and rat liver S9, primarily resulting from hydroxylation, oxidation, and desaturation, with generally similar metabolite profiles between species. In rats, ent-verticilide exhibited a systemic clearance of 29.6 mL/min/kg, a steady-state volume of distribution of 4.86 L/kg, and a terminal half-life of 6.85 h following intravenous administration. Absolute oral bioavailability was 10.5%. Overall, these findings show that ent-verticilide undergoes extensive oxidative hepatic metabolism and provide an initial DMPK framework for its continued preclinical development.

pharmacology and toxicology↗

RyR2-Mediated Ca2+ Leak Drives Progressive Arrhythmogenic Cardiomyopathy

Background Abnormal sarcoplasmic reticulum (SR) Ca2+ release through ryanodine receptor 2 (RyR2) is a well-established mechanism of ventricular arrhythmias. Whether persistent RyR2 dysfunction can also initiate the structural remodeling characteristic of arrhythmogenic cardiomyopathy (ACM) remains unknown. We tested the hypothesis that chronic RyR2-mediated Ca2+ leak is sufficient to couple electrical instability to progressive cardiomyopathy. Methods We generated a rabbit carrying the severe gain-of-function RyR2-V2475F mutation and characterized disease progression using longitudinal cardiac phenotyping, continuous electrocardiographic monitoring, cellular electrophysiology and Ca2+ imaging, histopathology, biochemical analyses, and single-nucleus RNA sequencing (snRNA-seq). Therapeutic potential was evaluated by continuous treatment with the selective RyR2 inhibitor ent-verticilide for two months. Results RyR2-V2475F rabbits developed spontaneous ventricular tachyarrhythmias, sudden cardiac death, and progressive right ventricular (RV)-dominant fibrofatty cardiomyopathy recapitulating major features of human ACM. Malignant ventricular arrhythmias preceded overt structural remodeling and were associated at the cellular level with early spontaneous Ca2+ release and early afterdepolarizations. Early disease was characterized by remodeling of excitation-contraction coupling with preserved SR Ca2+ load and contractile function despite RyR2 dysfunction; upon disease progression, these compensatory changes were accompanied by SR Ca2+ depletion, impaired RV contractility and reduced left ventricular filling. Single-nucleus transcriptomics identified early fibroblast expansion and predicted cardiomyocyte-centered paracrine signaling before advanced fibrofatty infiltration. Cardiomyocytes also exhibited an altered lipid-metabolic transcriptome and intracellular lipid accumulation, accompanied by enhanced mitochondrial Ca2+ uptake. Selective RyR2 inhibition markedly reduced ventricular tachycardia burden and preserved RV contraction and LV filling during disease progression. Conclusions Severe RyR2 gain-of-function can lead to both malignant ventricular arrhythmias and progressive arrhythmogenic cardiomyopathy in a large-animal model, establishing persistent intracellular Ca2+ dysregulation as a mechanistic link between electrical and structural heart disease. The ability of selective RyR2 inhibition to suppress arrhythmias and preserve cardiac function identifies RyR2 as a potentially actionable therapeutic target in arrhythmogenic cardiomyopathy.

physiology↗

Characterization of the Preclinical in Vitro and in Vivo Pharmacokinetic Properties of the Cyclic Oligomeric Depsipeptide Ryanodine Receptor 2 Inhibitor ent-Verticilide

ent-Verticilide is a synthetic cyclic oligomeric depsipeptide that inhibits ryanodine receptor 2 (RyR2)-mediated calcium (Ca) leak and has demonstrated antiarrhythmic activity in mice. This study characterized the preclinical absorption, distribution, metabolism, and pharmacokinetic properties of ent-verticilide and investigated factors affecting its oral exposure. ent-Verticilide was stable in rat plasma and simulated gastric and intestinal fluids but exhibited extensive plasma protein binding (>94%) and low apparent permeability in Caco-2 cells, with no evidence of pronounced net efflux. In rat and human liver microsomes, ent-verticilide underwent rapid NADPH-dependent metabolism, with an in vitro half-life of 5.43 min and 4.35 min, respectively, and a predicted hepatic extraction ratio of 0.90 and 0.92, respectively. Following intravenous administration in rats, ent-verticilide exhibited a systemic clearance of 25.5 mL/min/kg and a large steady-state volume of distribution (4.72 L/kg). Absolute oral bioavailability was approximately 16%. Simultaneous portal and systemic sampling estimated intestinal availability (FaFg) at 0.25 and hepatic availability (Fh) at 0.64, suggesting that processes occurring before hepatic entry are a major limitation to oral exposure. Pretreatment with the CYP inhibitor 1-aminobenzotriazole increased portal and systemic exposure approximately 10.6- and 18.5-fold, respectively, and increased apparent Fh to approximately 1. Collectively, these findings identify limited intestinal availability and CYP-mediated presystemic metabolism as important determinants of ent-verticilide exposure and provide a framework for its continued development as an RyR2-targeted therapeutic.

pharmacology and toxicology↗

ent-Verticilide B1 inhibits type 2 ryanodine receptor channels and is antiarrhythmic in Casq2-/- mice

Ca2+ leak from cardiac ryanodine receptor (RyR2) is an established mechanism of sudden cardiac death (SCD), whereby dysregulated Ca2+ handling causes ventricular arrhythmias. We previously discovered the RyR2-selective inhibitor ent-(+)-verticilide (ent-1), a 24-membered cyclooligomeric depsipeptide that is the enantiomeric form of a natural product (nat-(-)-verticilide). Here, we examined its 18-membered ring-size oligomer (ent-verticilide B1; "ent-B1") in single RyR2 channel assays, [3H]ryanodine binding assays, and in Casq2-/- cardiomyocytes and mice, a gene-targeted model of SCD. ent-B1 inhibited RyR2 single-channels and [3H]ryanodine binding with low micromolar potency, and RyR2-mediated spontaneous Ca2+ release in Casq2-/- cardiomyocytes with sub-micromolar potency. ent-B1 was a partial RyR2 inhibitor, with maximal inhibitory efficacy of less than 50%. ent-B1 was stable in plasma, with a peak plasma concentration of 1460 ng/ml at 10 min and half-life of 45 min after intraperitoneal administration of 3 mg/kg in mice. Both 3 mg/kg and 30 mg/kg ent-B1 significantly reduced catecholamine-induced ventricular arrhythmia in Casq2-/- mice. Hence, we have identified a novel chemical entity - ent-B1 - that preserves the mechanism of action of a hit compound and shows therapeutic efficacy. These findings strengthen RyR2 as an antiarrhythmic drug target and highlight the potential of investigating the mirror-image isomers of natural products to discover new therapeutics. Significance statementThe cardiac ryanodine receptor (RyR2) is an untapped target in the stagnant field of antiarrhythmic drug development. We have confirmed RyR2 as an antiarrhythmic target in a mouse model of sudden cardiac death and shown the therapeutic efficacy of a second enantiomeric natural product.

pharmacology and toxicology↗